Contraceptive patch

The contraceptive patch is a small adhesive patch that releases synthetic estrogen and a progestin through the skin. Brands in the US include Xulane (norelgestromin and ethinyl estradiol) and Twirla (levonorgestrel and ethinyl estradiol). The standard schedule is one patch per week for 3 weeks, then 1 patch-free week during which withdrawal bleeding occurs.

The patch is a combined hormonal contraceptive. Mechanism, efficacy, and cycle implications mirror the combined pill, with weekly dosing instead of daily.

This is informational, not medical advice. Contraceptive choice should be discussed with a qualified provider.

How it works

The patch releases steady levels of estrogen and progestin absorbed through the skin into the bloodstream. The contraceptive effects are the standard CHC triple:

  1. Ovulation suppression via HPO axis suppression and blunted LH surge.
  2. Cervical mucus thickening.
  3. Endometrial thinning.

Typical-use efficacy is around 91%, perfect-use above 99%.

A note on body weight: efficacy of the original Xulane patch drops in users above 198 lbs (90kg). Twirla has weight restrictions for use above similar thresholds. For users at or above these weights, providers often recommend a different method.

Cycle implications

Like other combined hormonal contraceptives, the patch suppresses the natural cycle. No follicular surge, no LH surge, no ovulation, no corpus luteum, no natural progesterone rise. The bleed during the patch-free week is withdrawal bleeding.

Cycle syncing by hormonal phase does not apply. The 28-day structural rotation can still be used as a productivity scaffold.

Common side effects

The side effect profile mirrors the combined pill, with the addition of skin-related effects:

  • Skin irritation at the patch site.
  • Breakthrough bleeding in the first 1 to 3 cycles.
  • Breast tenderness.
  • Headaches, including new or worsened migraines.
  • Nausea.
  • Mood changes in a subset of users.

One nuance worth knowing: the original Xulane patch delivers a higher cumulative estrogen exposure than a typical low-dose oral pill, which has been linked to a modestly higher blood clot risk than oral CHCs. Twirla was designed with a lower estrogen dose.

When to consider

  • Want a combined hormonal method without daily compliance.
  • Difficulty with daily pills but prefer not to use a long-acting method.
  • Comfortable with weekly patch changes and adherent skin contact.

When NOT to consider

  • Migraine with aura.
  • History of clots, stroke, heart attack.
  • Smoker over 35.
  • Uncontrolled high blood pressure.
  • Body weight above the labeled threshold for the specific patch.
  • Active estrogen-sensitive cancer.
  • Skin conditions that prevent patch adherence.

Related reading